RxDoctor Payments Data

Michael Messina, MD

Dermatology · Palm Desert, CANPI 1609073048

Payments from drug & device makers

$40,260in general payments, 2019–2025

Across 103 payments — averaging $390.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$19K
  • Bristol Myers Squibb$19K
  • Pfizer$247
  • Mimedx Group, Inc.$226
  • Revance Therapeutics, Inc.$210
  • Innovation Technologies Inc$188
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$4581%
  • Speaking & faculty fees$35,49488%
  • Travel & lodging$3701%
  • Food & beverage$3,93810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,260 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$2,145,863
Medicare patients
1,823
Services billed
16,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab30$225,375
OtezlaApremilast32$168,325
Enbrel SureclickEtanercept12$96,785
Dupixent PenDupilumab18$77,015
Dupixent SyringeDupilumab14$52,245
Fluorouracil171$10,787
Ketoconazole432$8,039
Metronidazole98$4,155
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc169$3,879
Clobetasol Propionate80$3,834
Triamcinolone Acetonide327$2,543
Doxycycline Hyclate90$2,424
ValacyclovirValacyclovir Hcl82$2,312
Azelaic Acid11$2,082
Betamethasone Dipropionate58$1,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$19,456$168,32532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,875 dermatology providers in California.

Other dermatology in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →